SHPT is a major comorbidity with adverse health consequences on CKD progression when present in the earlier stages, as well as on the risk of vascular calcifications, major adverse cardiovascular events (MACE), erythropoietin-resistant anemia, fractures, and death [4,9]. This evidence concerns the gene EPO and anemia (phenotype).